Abigail M Wolfe

20130052670, Feb 28, 2013

Jul 9, 2012

13/544554

Mary Savage - West Point PA, US
Paul Shughrue - West Chester PA, US
Abigail Wolfe - Ambler PA, US
Alexander McCampbell - Chalfont PA, US

MERCK - Rahway NJ

G01N 33/566
G01N 21/64

435 794, 436501

The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.

20150260731, Sep 17, 2015

Jun 3, 2015

14/729343

- Livermore CA, US
- Kenilworth NJ, US
Alexander McCampbell - West Point PA, US
Mary J. Savage - West Point PA, US
Paul J. Shughrue - West Point PA, US
Fubao Wang - West Point PA, US
Weirong Wang - West Point PA, US
Abigail L. Wolfe - West Point PA, US
Wei-Qin Zhao - West Point PA, US

G01N 33/68
C07K 16/18

This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

20140120037, May 1, 2014

Dec 20, 2013

14/137351

- Rahway NJ, US
Paul J. Shughrue - West Chester PA, US
Alexander McCampbell - Chalfont PA, US
Abigail L. Wolfe - Ambler PA, US

Merck Sharp & Dohme Corp. - Rahway NJ

G01N 33/68

424 92, 436501, 435 794

The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.